Series C AI companies in New York

Elysium Health’s mission is to solve the biggest challenges in health with science, to help people live healthier for longer. Elysium works directly with top scientists, clinicians and health professionals around the world to translate advances in science and technology into innovative health products that work. Our product development pipeline begins with research and development, continues with preclinical studies, and culminates with human clinical trials to demonstrate the safety and efficacy of products. Throughout this process, Elysium’s focus is to develop compounds found in nature that allow people to support their health proactively. Elysium is guided by a Scientific Advisory Board, which includes multiple winners of the Nobel Prize, as well as researchers and doctors who are experts in chemistry, physiology, neuroscience, complex chemical systems, biochemistry, and many other fields of study. Basis, Elysium Health’s first product, is a proprietary formulation of two ingredients designed to support long-term health at the cellular level. Basis is clinically proven to increase NAD+ levels, which decline with age. NAD+ is required for energy creation, regulating circadian rhythms, maintaining healthy DNA, and hundreds of other biological functions.

• Series C
• 85 employees
• Founded 2014

Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. We aim to change that.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, we have developed a platform to produce female reproductive cell lines. We use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Our team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Our first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.

• Series C
• 59 employees
• Founded 2020